利拉鲁肽长期降糖治疗对延缓2型糖尿病患者病情进展的随访研究  

Follow up Study of Liraglutide Long-term Hypoglycemic Treatment on Delaying Disease Progression in Patients with Type-2 Diabetes

作　　者：方兆东[1] 

机构地区：[1]广西中医药大学附属瑞康医院内分泌科,广西南宁530011

出　　处：《系统医学》2016年第11期49-51,共3页Systems Medicine

摘　　要：目的研究利拉鲁肽长期降糖治疗对延缓2型糖尿病患者病情进展的随访观察结果。方法选择2013年7月—2016年1月该院60例2型糖尿病患者作为研究对象,采用随机数表法分为两组,每组30例。对照组常规降糖治疗,观察组在常规治疗基础上加用利拉鲁肽,比较两组空腹血糖(FBG)、餐后2 h血糖(2h PG)及糖化血红蛋白(Hb Alc)等血糖控制效果及治疗前后体重指数(BMI)、空腹C肽、24 h尿蛋白及血肌酐等指标变化情况。结果观察组治疗后空腹血糖(FBG)、餐后2 h血糖(2h PG)及糖化血红蛋白(Hb Alc)分别为(7.24±0.61)mmol/L、(9.25±0.86)mmol/L及(5.78±0.72)%,均显著低于对照组,差异有统计学意义(P<0.05)。观察组治疗后空腹C肽为(2.68±0.87)ng/m L,显著高于治疗前和对照组治疗后,24 h尿蛋白和血肌酐分别为(74.34±13.27)mg和(87.46±10.21)μmol/L,均显著低于治疗前和对照组治疗后,差异有统计学意义(P<0.05)。结论利拉鲁肽对2型糖尿病患者降糖效果显著,能有效保护肾功能,防止心血管事件发生,对延缓糖尿病进程具有积极作用。Objective To study the follow up results of liraglutide long-term hypoglycemic treatment on delaying disease progression in patients with type-2 diabetes. Methods From July 2013 to January 2016, a total of 60 patients with type-2 diabetes accepted treatment in our hospital were taken as the clinical research objects, and they were randomly divided into observation group（30 cases）and control group（30 cases）. Both groups were treated with routine methods.Besides, the observation group received additional liraglutide in order to compare their blood sugar control effects including fasting blood glucose（FBG）, postprandial 2H plasma glucose（2h PG） and glycosylated hemoglobin（Hb Alc）, and changes such as body mass index（BMI） before and after treatment, fasting C-peptide and 24 h urinary protein and serum creatinine. Results After treatment, the fasting blood glucose（FBG）, postprandial 2H blood glucose（2h PG） and glycosylated hemoglobin（Hb Alc） in the observation group were respectively（7.24±0.61）mmol/L,（9.25±0.86）mmol/L and（5.78±0.72）% which were significantly lower than those in the control group, and their differences were statistically significant（P 0.05）; the Fasting C-peptide in the observation group was（2.68 ±0.87）ng/m L which was significantly higher than that in the control group and before treatment; the 24 h urinary protein and serum creatinine in the observation group were respectively（74.34±13.27）mg and（87.46±10.21）μmol/L which were significantly lower than those in the control group and before treatment, and their differences were statistically significant（P〈0.05）. Conclusion Liraglutide which can effectively protect the kidney has significantly hypoglycemic effect in patients with type 2-diabetes.

关 键 词：2型糖尿病 利拉鲁肽 降糖治疗 病情进展 

分 类 号：R587[医药卫生—内分泌]